Elif Alyanak supports clients with evidence-based research and analysis that spans a variety of healthcare sectors and stakeholders.
With a background in health policy and focus on vaccine and immunization research, she applies her skills in strategy, policy, recommendation development, and implementation science to a broad range of client projects.
Before joining Avalere, Elif held a variety of positions researching infectious disease prevention and vaccination at the Centers for Disease Control and Prevention (CDC). Formerly an Oak Ridge Institute for Science and Education (ORISE) fellow and senior analyst/epidemiologist within the National Center for Immunization and Respiratory Diseases (NCIRD), she supported many federal government vaccination studies and policy research. Additionally, Elif managed systematic reviews and meta-analyses and synthesized clinical vaccine literature while directly supporting the Advisory Committee on Immunization Practices (ACIP).
Elif has a BS in biology from the Georgia Institute of Technology, an MPH in health policy and management from Georgia State University, and a DrPH in health policy from George Washington University.
Authored Content
The ACIP’s December meeting resulted in a key change to the pediatric immunization schedule and signaled several potential changes to US vaccine coverage and access in 2026.
A new white paper examines the historical role of the Advisory Committee on Immunization Practices and its evolution following key federal policy changes.
At IDWeek, Avalere Health connected with industry and academic leaders on the evolving vaccine policy, access, value, and evidence landscape.
Differences in Medicare Part B and D coverage can impede access to vaccines, as demonstrated through 2020–2022 administration data of the herpes zoster vaccine.
The unwinding of COVID-era Medicaid continuous enrollment policies resulted in insurance coverage losses and challenged vaccine access for adults.
The ACIP’s first meeting with newly appointed members indicated the committee’s new direction, with potential impacts across US vaccine policy and access.
Avalere Health connected with other public health stakeholders and vaccine experts at World Vaccine Congress to discuss key policy, access, value, and evidence themes.
Policy actions in the first days of the Trump administration raise questions about the future role of key vaccine advisory committees.
As the processes, priorities, and membership within the ACIP evolve, vaccine manufacturers should adapt their evidence generation planning to support optimal review.
In this eBook, Avalere Health Advisory experts discuss the evolving vaccines ecosystem and analyze key policy issues affecting vaccines manufacturers.
In a new white paper, Avalere considers key questions related to strain selection, ACIP recommendation, and coverage and reimbursement of adult combination vaccines in development.
The World Vaccine Congress addressed the changing landscape of infectious diseases and vaccine types, approvals, recommendations, and reimbursement pathways.
WHO and VRBPAC recommendations to move back toward trivalent influenza vaccines may cause significant shifts in the global flu vaccine landscape.
In the fifth installment of our Respiratory Syncytial Virus (RSV) prevention series, Avalere experts discuss updates to the RSV prevention landscape, including newly approved products and recent Advisory Committee on Immunization Practices (ACIP) meeting discussions.
At its June meeting, ACIP reviewed data on several currently marketed and novel immunizations, highlighting the committee's focus on cost, accessibility, and equity.
Updated Avalere analysis finds MA beneficiaries with chronic conditions had fewer inpatient stays and ED visits than FFS Medicare beneficiaries.
The proposed vaccine definition would have a significant market impact on novel immunizations such as preventive immunoglobulins and therapeutic vaccines.
Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.
Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.
Tune into the third episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the future of RSV among older adults.
Tune into the third episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the future of RSV among older adults.
Tune into the second episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.
Tune into the second episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.
Tune into the first episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss how innovative offerings in the pediatric RSV immunization market will fit within the continuum of care and how the RSV preventive market will grow in the upcoming years.
Numerous novel respiratory syncytial virus (RSV) preventive products, including vaccines and monoclonal antibodies (mAbs), are in late-stage clinical development. Consequently, the RSV prevention landscape is expected to transform in the coming years. Adequate preparation to incorporate the use of these new tools should consider the regulatory and recommendation pathways and their implications for coverage and reimbursement.
On February 2, 2022, President Biden announced a revitalization of the Obama-era Cancer Moonshot Initiative, including updated goals to reduce cancer deaths by at least 50% over the next 25 years and improve the experience of cancer survivorship for patients and their families.